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Efficacy, Tolerability, and Safety of Calcipotriol 
Ointment in Disorders of Keratinization
Results of a Randomized, Double-blind, Vehicle-Controlled, 
Right/Left Comparative Study
Knud Kragballe, MD; Peter M. Steijlen, MD; Hans Henning Ibsen, M D; Peter C. M. van cle Kerkhof, MD; 
Jorgen Esmann, MD; Lars Halkier Sorensen, MD; Mads Buhl Axelsen, MD
Background and Design: Disorders of keratiniza­
tion are a heterogeneous group of diseases that have in 
common a defect in cornification. The bioactive form of 
vitamin D3 has been shown to modulate epidermal pro­
liferation and differentiation. The purpose of the pres­
ent study was to determine the effect of the synthetic vi­
tamin D3 calcipotriol in a randomized, double-blind, 
placebo-controlled, right/left comparative study. The 67 
patients included in the study were at least 12 years of 
age and had the following diseases: ichthyosis vulgaris 
(n=9), X-linked ichthyosis (n=8), congenital ichthyosis 
(n=10), hereditary palmoplantar keratoderma (n=20), 
keratosis pilaris (n=9), and Darier’s disease (n = ll) . Cal­
cipotriol ointment (50 fxg/g) and placebo (vehicle of cal­
cipotriol ointment) were applied to all patients twice daily 
for up to 12 weeks. The patients were allowed to use up 
to 120 g of calcipotriol ointment per week.
Results: At the end of the treatment regimen, calcipo­
triol ointment had an effect on the improvement of the ich-
thyoses, although to a variable degree. No therapeutic ef­
fect was detected in palmoplantar keratoderma or kera­
tosis pilaris. Eight of 12 patients with Darier’s disease had 
to be withdrawn because of skin irritation or a worsening 
of the disease. Skin irritation occurred in 18 cases (26%) 
only on the calcipotriol-treated side, and in one case (1%) 
only on the placebo-treated side. Nine cases (13%) had 
irritation on both sides. The amount of calcipotriol oint­
ment used per week was lowest in palmoplantar kerato­
derma (mean, 11.8 g/wk; range, 2.1 to 25.6 g/wk) and high­
est in congenital ichthyosis (mean, 59.3 g/wk; range, 11.4 
to 94.7 g/wk). There was no clinically significant change 
of serum calcium levels during the treatment period.
Conclusion: Short-term treatment with calcipotriol oint­
ment (50 (xg/g) used in amounts up to about 100 g/wk 
is moderately efficacious, well-tolerated, and safe in adult 
patients with various ichthyoses.
(Arch Dermatol. 1995;131:556-560)
1SORDERS OF keratiniza- mechanisms involve disordered keratino-
ltion comprise a hetero- cyte differentiation and/or proliferation,
geneous group of dis- In addition to the epidermal changes, some
eases characterized by dry of the disorders show dermal inflamma-
ancl scaly skin.1 They in- tion and immunologic changes. The bio-
clude the ichthyoses, Darier’s disease, pity- logically active form of vitamin D:J, 1,25-
riasis rubra pilaris, keratodermas, and fol- d i h y d r o x y v i t a m i n D 3, h as  b e e n
licular k e ra to ses . The d iso rd e rs  of demonstrated to stimulate the terminal dif-
keratinization are chronic, often inher- ferentiation of epidermal keratinocytes and
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ited, diseases with onset in childhood. 
Treatment is often unsatisfactory, al­
to inhibit the proliferation of epidermal ke- 
ra tin o cy tes .3 At least in v itro  1,25- 
though lubrication with ointm ents or dihydroxyvitamin D3 modifies differen-
creams may soften the skin, and topical 
preparations containing salicylic acid may
tiation  by stim ulating  the sw itch of 
suprabasal cells into cornified cells.4 Ap-
remove the scaling. In some of the disor- parently, 1,25-dihydroxyvitamin D3 in-
ders, retinoids administered topically, but 
mainly systemically, are effective.2 Be-
duces terminal differentiation of epider­
mal keratinocytes without changing their
cause of the associated risk of severe side keratin gene expression in vitro.5 By modi- 
effects, the systemic retinoids are only used 
in severe and widespread cases.
Although the disorders of keratini­
zation are a heterogeneous group of dis­
eases, they have in common a defect in cor­
nification. The underlying pathogenic
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PATIENTS AND METHODS PATIENT OUTCOMES
STUDY DESIGN AND PATIENTS
Clinical assessments were done separately at weeks 0, 2, 4, 
8, and 12 for the right and left sides of the body. The extent 
of the dyskeratotic involvement was recorded using the fol- 
The study was designed as a prospective, random ized, lowing scale: 0, no involvement; 1, less than 20%; 2, 20% to 
double-blind, right/left comparative study of calcipotriol 39%; 3,40% to 59%; 4,60% to 79%; and 5,80% to 100% for
(50 (xg/g) and placebo ointment (vehicle of calcipotriol oint­
m ent), both applied twice daily. The ingredients of the
arms
following
vehicle were disodium  hydrogen phosphate, polyoxyeth- in ichthyosis vulgaris and keratosis pilaris, scales and rough-
ylene-2-stearylether, propylene glycol, tetracemine diso- hyper
clium, DL-a-tocopherol, petrolatum, liquid paraffin, and wa- pigmentation; in Darter’s disease, scales, erythema, papules,
ter. The study was conducted in two centers in Denmark crust, and excoriation; in pityriasis rubra pilaris, scales, tliick-
ancl in one center in the Netherlands. Patients were not ness, and erythema; in hereditary palmoplantar kerato-
treated during summertime. The study was divided into two derma, scales, thickness, erythema, and Assuring; and in con-
phases. After a washout phase of 2 weeks during w hich the genital ichthyosis, scales, roughness, and erythema. These signs
patient used only an em ollient, the patients were given were assessed using the following scale: 0, absent; 1, slight;
double-blind treatment with calcipotriol ointm ent on  one 2, moderate; and 3, severe. Furthermore, the investigator as-
side of the body and placebo ointm ent on the other side sessed the overall response to the treatment compared with
for 12 weeks or until clearance on one side. The criterion baseline using the following 6-point scale: worse, no change,
for including patients was a clinical and histologic cliag- slight improvement, moderate improvement, marked im-
nosis of one of the follow ing dyskeratoses: ichthyosis vul- provement, and cleared. The patients assessed the overall re-
garis, X-linked ichthyosis, congenital ichthyosis, Darier’s spouse to treatment using the same scale. Blood samples for
disease, pityriasis rubra pilaris, hereditary palmoplantar kera- hematology and blood chemistry analyses, including serum
toderma, and keratosis pilaris. The diagnosis of X-linked total calcium levels, were taken before the start of treatment,
ichthyosis was based on an established human steroid sul- 
fatase deficiency.111
Patients had symmetrically located lesions and were 
at least 12 years of age. Excluded were patients w ith skin 
infection; atopic dermatitis; and system ic treatment with 
retinoids, corticosteroids, or PUVA within the 8-week pe­
riod prior to the w ashout phase. Also excluded were pa­
tients with hypercalcemia, high vitamin D or calcium in-
after 2 weeks’ treatment, and at the end of treatment.
STATISTICAL ANALYSIS
Comparison of treatment effects at the end of the double­
blind treatment period was based on intrapatient variations 
of the calcipotriol-treated side and the placebo-treated side. 
With respect to the investigator’s and patient’s overall as-
take, and significant renal or hepatic disease. W om en of sessment, the number of patients with the calcipotriol-
chilclbearing potential were only included if using an ad­
equate method of contraception. All patients gave their in-
consent.
All affected body areas, except for the face, scalp, 
and genital region, were treated with the study m edica­
tions. A maximum of '120 g was dispensed to each side 
of the body per week. Patients with affected areas on the 
face and genital region used an em ollient for these areas. 
All tubes were returned and w eighed  to determ ine the 
amount of ointment used. The use of other topical m edi­
cations or system ic treatment for dyskeratosis was not
treated side superior to the placebo-treatecl side were com­
pared with the number of patients with the placebo-treatecl 
side superior to the calcipotriol-treated side by binomial tests. 
Total sign score differences from baseline to end of double­
blind treatment period were calculated for both treatment 
sides separately and compared using a one-sample £ test.
For adverse events the number of patients reporting 
adverse events on the calcipotriol-treated side only was com­
pared with the number of patients reporting adverse events 
on the placebo-treated side only by binomial tests.
All statistical tests were two sided, and a 5% signifi­
cance level was used.
uuinuimi
lying the epidermal growth pattern, vitamin D j may im­
prove disorders of keratinization. However, neither X-
determine whether topical calcipotriol is effective, tol­
erated, and safe in disorders of keratinization.
osis nor ic zaris has res
RESULTS
lin k ed  ic
to treatment with either oral la-hydroxyvitamin Djft or
topical 1,25-dihydroxyvitamin D:}.7
Calcipotriol is a synthetic vitamin D analogue that Sixty-nine patients were randomized to receive treat­
ies as effective as 1,25-dihydroxyvitamin D* in binding to ment (Table 1 ) .  However, one patient included in the 
the vitamin D receptor and in stimulating epidermal dif- Darier’s disease group had Hailey-Hailey disease. Fur- 
ferentiation." Compared with 1,25-dihydroxyvitamin D:Ji thermore, one patient with lamellar ichthyosis left the 
calcipotriol, however, is about 100 to 200 times less po- study before any collection of efficacy or safety data. There- 
_______ _ __________________  in rats.8 In clini- fore, efficacy and safety data were only available for 67
cal studies, calcipotriol ointment (50 (xg/g) has been patients. The subgroup of hereditary palmoplantar kera-
shown to be effective and safe for the treatment of pso- toderma had 20 patients randomized, while the other
'nt in its eliect on ce
riasis vulgaris.0 The purpose ; present s groups consisted of eight to 12 patients each. The sub-
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group of congenital ichthyosis was heterogeneous, con­
sisting of one patient with epiclermolytic hyperkeratosis 
(bullous ichthyosiform erythroderma of Brocq, autoso- 
mally dominantly inherited), two patients with lamellar 
ichthyosis (nonerythrodermic autosomal recessive la­
mellar ichthyosis), two patients with Sjogren-Larsson syn­
drome, one patient with ichthyosis linearis circumflexa, 
two patients with congenital ichthyosiform erythro­
derma (erythrodermic autosomal recessive lamellar ich­
thyosis) , and two patients with ichthyosis bullosa of 
Siemens. No case of pityriasis rubra pilaris was random­
ized., At baseline there was no clinically significant dif­
ference in the total sign score on the right and left sides 
(data not shown). Fifteen of the 69 randomized patients 
withdrew from the double-blind treatment regimen 
(Table 2). Adverse events were the reason for with­
drawal in nine of 15 cases (see below). It was remark-
Table 1. Number and Demographic Data 
of Patients Randomized
Disease n
No. (%) of 
Male Subjects
Age, y 
(Mean, Range)
Ichthyosis vulgaris 
X-linked ichthyosis
ichthyosis 
Darier’s disease 
Keratoderma 
Keratosis pilaris 
All Patients
a
8
11
12
20
9
69
5(56)
8 (100) 
5 (45)
7 (58) 
12 (60)
1 (11) 
38 (55)
34.1 (16-52)
34.4 (16-50)
32.4 (16-55)
38.6 (18-79)
29.7 (11 -57)
23.4 (16-45) 
32.0 (11-79)
Table 2. Reason for Withdrawal From 
Double-blind Treatment
Disease
No. of 
Adverse 
Events
No. of 
Unacceptable 
Responses
No. of
Voluntary
Defaults
Total
No.
Ichthyosis vulgaris 
(n=9)
X-linked Ichthyosis 
(n=8)
Congenital ichthyosis 
(n=11)
Darier’s disease (ns12)
Palmoplantar keratoderma 
(n=20)
Keratosis pilaris (n*9)
Total (N=69)
0
1
0
6
1
1
9
0 0 0
0 1 2
0 1 1
1 1* 8
0 1 2
1 0 2
2 4 15
!|! This patient had Hailey-Hailey disease.
able that seven of 12 patients with Darier’s disease with­
drew  because of lesional-perilesional irritation or 
worsening of the disease. In accordance with the high 
number of withdrawals, the mean duration of double- 
blind treatment was only 6.1 weeks in Darier’s disease, 
compared with 9.6 to 12,3 weeks in the other sub­
groups. Table 3 shows the investigator’s overall assess­
ment of the treatment response to calcipotriol and pla­
cebo at the end of treatment. Marked improvement or 
clearance was observed on the calcipotriol-treatecl side 
in five of nine cases with ichthyosis vulgaris, in four of 
eight patients with X-linkecl ichthyosis, and in eight of 
10 cases with congenital ichthyosis, but the difference 
between calcipotriol and placebo was only statistically 
significant for X-linkecl ichthyosis (P=.03) and congeni­
tal ichthyosis (P=.02). The patient’s overall assessment 
at the end of the treatment period is tabulated in the same 
way (Table 4). According to the patients, marked im­
provement or clearance was observed on the calcipotriol- 
treated side in four of nine patients with ichthyosis vul­
garis, in four of eight patients with X-linked ichthyosis, 
and in seven of 10 patients with congenital ichthyosis. 
Only in X-linked ichthyosis did the difference between 
calcipotriol and placebo reach statistical significance
(P=.03).
The total sign score, defined as the sum of the se­
verity scores for each side of the body, could have a mini­
mum range of 0 to 6 for ichthyosis vulgaris and kerato­
sis pilaris and a maximum range from 0 to 15 for Darier’s 
disease. The decrease in the total sign score at the end of 
the treatment period was greater on the calcipotriol- 
treated side than on the placebo-treated side in ichthyo­
sis vulgaris, X-linked ichthyosis, and congenital ichthyo­
sis (Figure) In congenital ichthyosis this reduction in 
the total sign score on the calcipotriol-treated side was 
statistically highly significant compared with the placebo- 
treated side (P=.0015) (Figure). There was no statisti­
cally significant difference between calcipotriol and pla­
cebo in the mean total sign score or overall assessment 
in other subgroups of dyskeratosis (data not shown).
The adverse events reported or observed during the 
treatment period were almost exclusively localized to the 
skin and consisted almost exclusively of various forms 
of lesional and perilesional irritation (Table 5). No ir­
ritation was detected in congenital ichthyosis. Lesional- 
perilesional irritation was more often seen on the calci­
potriol-treatecl side (PC.001). Skin irritation was most 
common in X-linked ichthyosis and Darier’s disease. 
While only a single patient with X-linked ichthyosis was
Table 3. Investigator’s Overall Assessment of Treatment Response at End of Treatment Period
Calcipotriol/Placebo, No. of Patients
No Slight Moderate Marked
Disease Cleared Worse Change Improvement Improvement Improvement Cleared
Ichthyosis vulgaris (n=9) 0/0 0/0 2/4 2/4 5/0 0/1
X-linked ichthyosis (n=8) 0/0 1/2 0/4 3/2 4/0 0/0
Congenital ichthyosis (n=10) 0/0 1/4 0/4 1/1 8/1 0/0
Keratoderma (n=20) 0/0 9/11 6/5 3/1 2/2 0/1
Keratosis pilaris (n=9) 2/1 1/2 2/3 2/3 2/0 0/0
Darier’s disease (n=11) 8/5 0/4 2/0 1/2 0/0 0/0
■
ARCH DERMATOL/VOL 131, MAY 1995
558
Tabic 4. Patient s Overall Assessment of Treatment Response at End of Treatment Period
Disease Cleared
Ichthyosis vulgaris (n=9) 
X-linked ichthyosis (n=8)* 
Congenital ichthyosis (n=10) 
Keratoderma (n=20) 
Keratosis pilaris (n=9) 
Darier’s disease (n=11)
Calcipotriol/PIacebo, No. of Patients
Worse
0/0 
0/1 
0/1 
0/0 
2/1 
8/5
No
0/0
0/3
1/4
8/10
2/4
0/3
*For one of the patients, the calcipotriol-treated side was not assessed.
Slight
Improvement
3/5 
0/2 
0/3 
8/5 
0/0 
1/1
Moderate
Improvement
Marked
Cleared
2/3
3/1
2/1
3/2
3/3
2/1
4/0
4/1
0/0
1/2
2/1
0/1
0/1
0/0
0/1
0/0
0/0
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Change in the mean total sign score during treatment with calcipotriol 
ointment (50 ¡¿g/g) and placebo ointment in ichthyosis vulgaris (n=9), 
X-linked ichthyosis (n=8), and congenital ichthyosis (n=10).
withdrawn because of skin irritation, six patients with 
D a rie r’s disease w ithdrew  because of lesional- 
perilesional irritation. The amount of calcipotriol oint­
ment used per week was lowest in palmoplantar kerato-
Table 5. Lesional-Perilesional Irritation Reported 
and/or Observed in Disorders of Keratinization
Calcipotriol Placebo Both
Disease
Side,
No. (%)
Side,
No. (%)
Sides, 
No. (%)
ichthyosis vulgaris (n=9) 2(22) 1(11)
4* '
0
X-linked Ichthyosis (n=8) 6 (57) 0 0
Congenital ichthyosis (n=10) 0 0 0
Palmoplantar keratoderma (n=20) 5 (25) 0 2(10)
Keratosis pilaris 2(22) 0 2 (22)
Darier’s disease (n=12) 3(25) 0 5 (42)
Total No. of Irritations 18 (26) 1 (1 ) 9
derma (mean, 11.8 g/wk; range, 2.1 to 25.6 g/wk) and 
highest in congenital ichthyosis (mean, 59.3 g/wk; range,
11.4 to 94.7 g/wk). With respect to the change in the se­
rum total calcium level from baseline to the end of the 
treatment period, the subgroup X-linked ichthyosis 
showed a minor, but statistically significant, reduction 
(P=.045). No subgroup showed any statistically signifi­
cant increase in the serum total calcium level (data not 
shown).
COM M ENT
The results of the present study indicate that topical treat-
with
forms of ichthyosis
toderma and keratosis pilaris seem to be unresponsive 
to calcipotriol, whereas Darier’s disease may worsen dur­
ing treatment with calcipotriol, probably due to the ir­
ritating capacity of calcipotriol ointment. The presence 
of eroded and fissured lesions in Darier’s disease maybe 
the reason for the increased susceptibility to become ir­
ritated by calcipotriol ointment. Except for Darier’s dis­
ease, the cutaneous side effects in the dyskeratotic dis­
orders were similar to those observed in psoriasis with 
respect to their nature, severity, and frequency.9 Among 
the ichthyoses, X-linked ichthyosis and congenital ich­
thyosis were particularly responsive to calcipotriol. The 
group with congenital ichthyosis is very heterogeneous, 
and the low number of patients in each subtype does not 
allow any conclusions as to any variation in the respon­
siveness to calcipotriol. In contrast to calcipotriol, nei­
ther oral la-hydroxyvitamin D36 nor topical 1,25-
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dihyclroxyvitamin D37 is reported to improve X-linked warrants further investigation. If topical calcipotriol is 
ichthyosis or ichthyosis vulgaris. The reason for this ap- found to be efficacious and safe in long-term large-scale
' J  - M |  J ^n ■ ■
_ r^ -É
parent discrepancy is most likely that la-hydroxyvita- studies, this treatment may be of great benefit to pa-
min D3 and 1,25-dihydroxyvitamin D3 were tients severely affected osis. Also, u s
that were too low. Thus, the applied concentration of 1,25- investigated whether it is beneficial to combine calcipo- 
dihydroxyvitamin D3 (1 jjug/g) has no significant effect triol with a retinoid. In addition to a simple additive el- 
on psoriasis.11,12 feet of these two classes of compounds, an interaction
A major concern during treatment with vitamin D might occur on the molecular level, leading to a syner- 
analogues is whether percutaneously absorbed vitamin 
D may change calcium metabolism. In large-scale stud­
ies of psoriasis, it has been found that a weekly dose of 
up to 100 g of calcipotriol ointment (50 |xg/g) does not 
change the serum calcium levels.Q Furthermore, the bio­
chemical markers of calcium and bone metabolism do 
not change in psoriatic subjects receiving a mean calci­
potriol dose of 40 g/wk13 or 100 g/wk.14 In the present 
study, during which patients were i
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ucts, Copenhagen, Denmark.
The authors want to thank Suren
fo r  the statistical analyses.
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to use up to
120 g/wk, no significant changes in serum calcium lev­
els were found. This indicates that patients 
ders of keratinization are not more likely than psoriatic 
subjects to develop hypercalcemia after topical applica­
tion of calcipotriol. However, it should be borne in mind 
that only half of the affected skin lesions were treated with 
calcipotriol. In some of the patients with more wide­
spread disease, it might have been impossible to treat all 
lesions with the allowed amount of calcipotriol (120 
g/wk). As recommended for psoriasis, calcipotriol oint­
ment (50 (xg/g) was applied twice daily in the dyskera­
toses. It is, however, possible that application oi calci­
potriol ointment once daily is efficacious for the treatment 
of ichthyosis. If so, 120 g of calcipotriol ointment per weel 
might be sufficient in most patients.
Vitamin D and its analogues have multiple actions 
on the cellular and molecular levels, and it still has not 
been sorted out whether vitamin D analogues work in 
psoriasis by modifying keratinocyte differentiation/ 
proliferation or whether their immunosuppressive ef­
fects are important for their antipsoriatic effect. The fact 
that treatment with calcipotriol can improve the ichthyo- 
ses supports the idea that calcipotriol in vivo has an ef­
fect on epidermal differentiation and/or proliferation in­
dependent of immunomodulation.
It can be concluded that topical treatment with cal­
cipotriol (50 (xg/g) for 12 weeks can induce a moderate 
improvement of various forms of ichthyoses. While cal­
cipotriol is well tolerated in ichthyosis, it may worsen 
Darier’s disease, probably due to its irritating capacity. 
Although ichthyosis may be responsive to calcipotriol 
treatment, large-scale studies, but especially long-term 
studies, are needed to confirm the present resul ts. I f cal­
cipotriol ointment is used for the treatment of ichthyo­
sis, it is important that the weekly dose be kept below 
120 g. If calcipotriol is applied twice daily, about 15% to 
20% of the body surface can be treated, but application 
once daily makes it possible to increase the treated skin 
area. The safety and efficacy of this alternative approach
Reprint requests to Department of Dermatology>, 
Marselishorg Hospital, DK-8000 Aarhus C, Denmark (Dr
Kran
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